216 related articles for article (PubMed ID: 25354685)
1. Phospholipid-modified PEI-based nanocarriers for in vivo siRNA therapeutics against multidrug-resistant tumors.
Essex S; Navarro G; Sabhachandani P; Chordia A; Trivedi M; Movassaghian S; Torchilin VP
Gene Ther; 2015 Mar; 22(3):257-266. PubMed ID: 25354685
[TBL] [Abstract][Full Text] [Related]
2. P-glycoprotein silencing with siRNA delivered by DOPE-modified PEI overcomes doxorubicin resistance in breast cancer cells.
Navarro G; Sawant RR; Biswas S; Essex S; Tros de Ilarduya C; Torchilin VP
Nanomedicine (Lond); 2012 Jan; 7(1):65-78. PubMed ID: 22191778
[TBL] [Abstract][Full Text] [Related]
3. Codelivery of doxorubicin and MDR1-siRNA by mesoporous silica nanoparticles-polymerpolyethylenimine to improve oral squamous carcinoma treatment.
Wang D; Xu X; Zhang K; Sun B; Wang L; Meng L; Liu Q; Zheng C; Yang B; Sun H
Int J Nanomedicine; 2018; 13():187-198. PubMed ID: 29343957
[TBL] [Abstract][Full Text] [Related]
4. siRNA-mediated down-regulation of P-glycoprotein in a Xenograft tumor model in NOD-SCID mice.
Abbasi M; Aliabadi HM; Moase EH; Lavasanifar A; Kaur K; Lai R; Doillon C; Uludağ H
Pharm Res; 2011 Oct; 28(10):2516-29. PubMed ID: 21638135
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of Small Interfering RNA Delivery via Arginine-Rich Polyethylenimine-Based Polyplex in Metastatic and Doxorubicin-Resistant Breast Cancer Cells.
Lu S; Morris VB; Labhasetwar V
J Pharmacol Exp Ther; 2019 Sep; 370(3):902-910. PubMed ID: 30940690
[TBL] [Abstract][Full Text] [Related]
6. A self-assembled polyjuglanin nanoparticle loaded with doxorubicin and anti-Kras siRNA for attenuating multidrug resistance in human lung cancer.
Wen ZM; Jie J; Zhang Y; Liu H; Peng LP
Biochem Biophys Res Commun; 2017 Dec; 493(4):1430-1437. PubMed ID: 28958938
[TBL] [Abstract][Full Text] [Related]
7. Multifunctional PLGA Nanobubbles as Theranostic Agents: Combining Doxorubicin and P-gp siRNA Co-Delivery Into Human Breast Cancer Cells and Ultrasound Cellular Imaging.
Yang H; Deng L; Li T; Shen X; Yan J; Zuo L; Wu C; Liu Y
J Biomed Nanotechnol; 2015 Dec; 11(12):2124-36. PubMed ID: 26510307
[TBL] [Abstract][Full Text] [Related]
8. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
9. Doxorubicin and siRNA Codelivery via Chitosan-Coated pH-Responsive Mixed Micellar Polyplexes for Enhanced Cancer Therapy in Multidrug-Resistant Tumors.
Butt AM; Amin MC; Katas H; Abdul Murad NA; Jamal R; Kesharwani P
Mol Pharm; 2016 Dec; 13(12):4179-4190. PubMed ID: 27934479
[TBL] [Abstract][Full Text] [Related]
10. Quick synthesis of a novel combinatorial delivery system of siRNA and doxorubicin for a synergistic anticancer effect.
Chen M; Wang L; Wang F; Li F; Xia W; Gu H; Chen Y
Int J Nanomedicine; 2019; 14():3557-3569. PubMed ID: 31190812
[No Abstract] [Full Text] [Related]
11. siRNAs targeting multidrug transporter genes sensitise breast tumour to doxorubicin in a syngeneic mouse model.
Tiash S; Chowdhury EH
J Drug Target; 2019 Mar; 27(3):325-337. PubMed ID: 30221549
[TBL] [Abstract][Full Text] [Related]
12. Delivery of siRNA by MRI-visible nanovehicles to overcome drug resistance in MCF-7/ADR human breast cancer cells.
Lin G; Zhu W; Yang L; Wu J; Lin B; Xu Y; Cheng Z; Xia C; Gong Q; Song B; Ai H
Biomaterials; 2014 Nov; 35(35):9495-507. PubMed ID: 25155545
[TBL] [Abstract][Full Text] [Related]
13. Reduction/photo dual-responsive polymeric prodrug nanoparticles for programmed siRNA and doxorubicin delivery.
Wu M; Li J; Lin X; Wei Z; Zhang D; Zhao B; Liu X; Liu J
Biomater Sci; 2018 May; 6(6):1457-1468. PubMed ID: 29770812
[TBL] [Abstract][Full Text] [Related]
14. In Vivo Antitumor Activity of Folate-Conjugated Cholic Acid-Polyethylenimine Micelles for the Codelivery of Doxorubicin and siRNA to Colorectal Adenocarcinomas.
Amjad MW; Amin MC; Katas H; Butt AM; Kesharwani P; Iyer AK
Mol Pharm; 2015 Dec; 12(12):4247-58. PubMed ID: 26567518
[TBL] [Abstract][Full Text] [Related]
15. pH-responsive complexes using prefunctionalized polymers for synchronous delivery of doxorubicin and siRNA to cancer cells.
Dong DW; Xiang B; Gao W; Yang ZZ; Li JQ; Qi XR
Biomaterials; 2013 Jul; 34(20):4849-59. PubMed ID: 23541420
[TBL] [Abstract][Full Text] [Related]
16. Overcoming Multidrug Resistance by Codelivery of MDR1-Targeting siRNA and Doxorubicin Using EphA10-Mediated pH-Sensitive Lipoplexes: In Vitro and In Vivo Evaluation.
Zhang J; Du Z; Pan S; Shi M; Li J; Yang C; Hu H; Qiao M; Chen D; Zhao X
ACS Appl Mater Interfaces; 2018 Jun; 10(25):21590-21600. PubMed ID: 29798663
[TBL] [Abstract][Full Text] [Related]
17. Targeting ETS1 with RNAi-based supramolecular nanoassemblies for multidrug-resistant breast cancer therapy.
Wu M; Liu X; Jin W; Li Y; Li Y; Hu Q; Chu PK; Tang G; Ping Y
J Control Release; 2017 May; 253():110-121. PubMed ID: 28302581
[TBL] [Abstract][Full Text] [Related]
18. Optimized polyethylenimine (PEI)-based nanoparticles for siRNA delivery, analyzed in vitro and in an ex vivo tumor tissue slice culture model.
Ewe A; Höbel S; Heine C; Merz L; Kallendrusch S; Bechmann I; Merz F; Franke H; Aigner A
Drug Deliv Transl Res; 2017 Apr; 7(2):206-216. PubMed ID: 27334279
[TBL] [Abstract][Full Text] [Related]
19. Codelivery of an optimal drug/siRNA combination using mesoporous silica nanoparticles to overcome drug resistance in breast cancer in vitro and in vivo.
Meng H; Mai WX; Zhang H; Xue M; Xia T; Lin S; Wang X; Zhao Y; Ji Z; Zink JI; Nel AE
ACS Nano; 2013 Feb; 7(2):994-1005. PubMed ID: 23289892
[TBL] [Abstract][Full Text] [Related]
20. Restoration of chemosensitivity by multifunctional micelles mediated by P-gp siRNA to reverse MDR.
Shen J; Wang Q; Hu Q; Li Y; Tang G; Chu PK
Biomaterials; 2014 Oct; 35(30):8621-34. PubMed ID: 25002258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]